Third Pole Therapeutics

Focus: Third Pole Therapeutics is a biotechnology company focused on inhaled nitric oxide delivery systems for respiratory indications, headquartered in Waltham, MA. The company operates at an early clinical stage with a single active trial.

Respiratory

Profile data last refreshed 11h ago · AI intelligence enriched 3w ago

Total Funding

$25M

Open Jobs

Should You Work at Third Pole Therapeutics?

AI assessment

Third Pole is a speculative early-stage play suitable only for risk-tolerant candidates seeking equity upside; limited hiring and transparency make this a high-uncertainty career move.

Why Work Here

Focused technology platform in inhaled NO delivery addresses a validated respiratory market with pulmonary hypertension as lead indication.

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Inhaled Nitric Oxide

Hypertension, Pulmonary

N/A

Clinical Trials (1)

NCT05867914Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD

N/A

Help build intelligence for Third Pole Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage company offers potential equity upside and hands-on involvement in clinical program development.

Located in Waltham, MA biotech hub with access to regional pharma talent and networks.

Watch Out For

Minimal hiring activity (1 active role in IT) signals early-stage constraints on team expansion and career trajectory.
Single clinical trial and limited public financial data create uncertainty around funding runway, clinical success probability, and long-term viability.
No revenue, no marketed products, and pre-clinical stage increase cash burn risk and restructuring exposure.

Generated by Claude from Third Pole Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.